A biotech fledgling cross-bred in France and Switzerland launches to take on liver problems of global dimensions
Drug development is a global business, but when it comes to raising venture cash, startups in Europe and the US are often operating on completely different scales.
Consider Alentis Therapeutics, a biotech incubated in Basel, Switzerland that says it has found the “master switch” for a number of advanced liver diseases, from fibrosis due to NASH to hepatocellular carcinoma. The Series A grant total: $13.2 million (CHF 13.5 million).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.